Review and Guide,it has been shown to protect the kidneys

The relationship between Ozempic (semaglutide) and kidney function is a topic of growing interest, particularly for individuals managing type 2 diabetes and chronic kidney disease (CKD). While Ozempic is primarily known for its role in blood sugar control, emerging research and recent approvals highlight its significant effects on kidney health. This article delves into how semaglutide, also known as Ozempic, impacts renal function, exploring both its potential benefits and reported adverse events.

Ozempic's Approval for Kidney Health:

A significant development in the understanding of Ozempic's renal benefits came with its expanded approval by regulatory bodies. The U.S. Food and Drug Administration (FDA) approved Ozempic for use in people with type 2 diabetes and kidney disease on January 28, 2025. This approval was based on pivotal trial data, such as the FLOW study, which demonstrated a substantial reduction in kidney disease progression. Specifically, semaglutide was shown to reduce the risk of kidney disease worsening, renal failure, and cardiovascular death by 24% compared to a placebo. Similar approvals have been granted by other health authorities, such as the TGA, which has approved semaglutide for reducing the risk of kidney function decline in adults with type 2 diabetes and chronic kidney disease.

Positive Effects on Kidney Function:

The effects of semaglutide on kidney function are multifaceted. Studies indicate that Ozempic can protect kidneys through several mechanisms:

* Reducing Albuminuria: A key indicator of kidney damage is the presence of albumin in the urine (albuminuria). Research, including a 24-week trial, showed that semaglutide led to a significant 52% reduction in albuminuria, thereby improving kidney health. The mechanism by which semaglutide reduces albuminuria may involve both direct intrarenal and indirect effects outside of the kidneys.

* Slowing Disease Progression: The FLOW trial, specifically designed to evaluate renal function with semaglutide once weekly, found that patients on semaglutide experienced a 24% reduction in kidney disease-related events. This translates to a slower yearly decline in estimated glomerular filtration rate (eGFR) levels, indicating preserved kidney function. The kidneys were better maintained with semaglutide in these study participants.

* Reducing Inflammation: One leading theory suggests that semaglutide may reduce inflammation, a process that often exacerbates kidney disease. By mitigating inflammation, Ozempic can contribute to better kidney health.

* Improving Blood Flow: Beyond its glucose-lowering capabilities, Ozempic has been shown to protect the kidneys by improving blood flow.

Understanding the Impact of Semaglutide on Renal Health:

For individuals with type 2 diabetes and chronic kidney disease (CKD), Ozempic offers a promising therapeutic option. The drug is indicated for adults with T2D and CKD1 to reduce the risk of sustained eGFR decline and end-stage kidney disease. This means that Ozempic can be used in patients with chronic kidney disease (CKD), including those with moderate to severe renal impairment. Unlike some diabetes medications, Ozempic appears to be tolerated by most individuals with CKD4 or greater, despite associated gastrointestinal side effects similar to those observed in the general population.

Potential Risks and Considerations:

While the benefits of semaglutide for kidney function are increasingly recognized, it's important to acknowledge potential risks. Postmarketing reports have indicated instances of acute kidney injury (AKI) and worsening CKD in patients taking semaglutide. The effect of semaglutide on kidney function has not been well established in all contexts, and the FDA label for Ozempic lists "acute kidney injury and worsening of chronic renal failure" as a potential adverse reaction.

It's crucial to note that in some reported cases of acute renal failure associated with semaglutide, the kidney damage was reversible after the drug was discontinued. The half-life of Ozempic is approximately seven days, meaning renal function recovered after a period of withdrawal. Factors such as substantial weight loss, a known effect of semaglutide, may have contributed to declines in kidney function in some individuals.

Furthermore, there is a potential risk of kidney injury associated with both Wegovy and Ozempic use, as semaglutide is cleared from the blood through the kidneys. However, for most individuals with type 2 diabetes and kidney disease, the benefits of Ozempic in slowing disease progression appear to outweigh these risks.